PRESTIGE CONSUMER HEALTHCARE INC. Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) reported Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation of $900.00 thousand for the 12-month period ending 2017-03-31, per its 10-K filed 2019-05-13.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation · last filed 2019-05-13
- PRESTIGE CONSUMER HEALTHCARE INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2017 was $900.00K, a 54.08% decline from fiscal 2016.
- PRESTIGE CONSUMER HEALTHCARE INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2016 was $1.96M, a 47.37% increase from fiscal 2015.
- PRESTIGE CONSUMER HEALTHCARE INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2015 was $1.33M, a 19.39% decline from fiscal 2014.
- PRESTIGE CONSUMER HEALTHCARE INC. adjustments to additional paid in capital, income tax benefit from share-based compensation for fiscal 2014 was $1.65M.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation 12 month |
|---|---|
| 2017-03-31 | $900.00K 10-K · filed 2019-05-13 |
| 2016-03-31 | $1.96M 10-K · filed 2018-05-10 |
| 2015-03-31 | $1.33M 10-K · filed 2017-05-17 |
| 2014-03-31 | $1.65M 10-K · filed 2016-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |